Immunocore has a robust pipeline of wholly-owned and partnered programmes.
Alongside high value proprietary programmes, Immunocore has co-discovery and co-development programmes with Lilly and discovery programmes, including milestones and royalties, with Genentech, GlaxoSmithKline and AstraZeneca (MedImmune).
